Skip to content

US · ELV · MEDICAL - HEALTHCARE PLANS

Elevance Health Inc. (ELV) intrinsic value and stock valuation

$394.48as of 2026-11-21 · Mkt cap 85.49B

Data updated · price as of 2026-11-21

OvervaluedIC value is 20–50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Elevance Health Inc. DCF and intrinsic value

InvestorsCraft values ELV with the Chepakovich two-stage DCF model — currently rated overvalued. How the model works · Run your own DCF prefilled from ELV’s statements →

Elevance Health Inc. Graham Number

Graham Number: $337.65d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Medical - Healthcare Plans Indianapolis, IN 46204 elevancehealth.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$199.1B+10.3% 5y CAGRd
20112025
Net income
$5.66B+4.4% 5y CAGRd
20112025
Free cash flow
$3.17B-20% 5y CAGRd
20112025
Total equity
$44B+5.8% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$199.1B$176.8B$171.3B$156.6B$138.6B
Operating income$8.11B$8.89B$8.75B$8.45B$8.95B
Net income$5.66B$5.98B$5.99B$5.89B$6.1B
EPSd$25.5M$25.7M$25.2M$24.3M$24.7M
Operating cash flow$4.29B$5.81B$8.06B$8.4B$8.36B
Capital expenditure-$-1.12B-$-1.26B-$-1.3B-$-1.15B-$-1.09B
Free cash flow$3.17B$4.55B$6.77B$7.25B$7.28B
Total assets$121.5B$116.9B$108.9B$102.8B$97.5B
Total debt$33.2B$32.7B$26.7B$25.8B$24.9B
Net debt$23.7B$24.4B$20.1B$18.4B$20B
Total equity$44B$41.4B$39.4B$36.3B$36.1B
Cash and short-term investments$9.49B$8.29B$6.53B$7.39B$4.88B
Income statement
20252024202320222021
Revenue$199.1B$176.8B$171.3B$156.6B$138.6B
Cost of revenue$148.2B$127.6B$124.3B$116.6B$102.6B
Gross profit$50.9B$49.2B$47B$40B$36B
Research and development expenses$0.00$0.00$0.00$0.00$0.00
Selling, general and administrative expenses$0.00$0.00$0.00$0.00$0.00
Other expenses$42.8B$40.4B$38.3B$31.5B$27B
Operating expenses$42.8B$40.4B$38.3B$31.5B$27B
Cost and expenses$191B$167.9B$162.6B$148.1B$129.7B
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$1.4B$1.19B$1.03B$851M$798M
Depreciation and amortization$1.55B$1.39B$1.75B$1.68B$1.3B
Ebitda$9.66B$10.5B$10.5B$10.1B$10B
Operating income$8.11B$8.89B$8.75B$8.45B$8.95B
Total other income/expenses, net-$-1.4B-$-984M-$-1.03B-$-851M-$-1.02B
Income before tax$6.71B$7.9B$7.72B$7.6B$7.93B
Income tax expense$1.05B$1.93B$1.72B$1.71B$1.83B
Net income$5.66B$5.98B$5.99B$5.89B$6.1B
Weighted average shares outstanding$221.8M$232.9M$233.1M$240M$243.8M
Weighted average diluted shares outstanding$221.8M$232.9M$237.4M$242.8M$246.8M
Balance sheet
20252024202320222021
Cash and short-term investments$9.49B$8.29B$6.53B$7.39B$4.88B
Net receivables$15.2B$13.1B$12.5B$11.7B$9.69B
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$24.7B$21.3B$19B$19.1B$14.6B
Property, plant and equipment, net$5.13B$5.22B$4.94B$4.92B$4.55B
Goodwill and intangible assets$39.5B$40.4B$35.6B$34.7B$34.8B
Long-term investments$38.6B$37.2B$36.8B$33.3B$34B
Total non-current assets$96.8B$95.5B$89.9B$83.6B$82.9B
Total assets$121.5B$116.9B$108.9B$102.8B$97.5B
Accounts payable$17.1B$15.7B$16.1B$15.6B$13.5B
Short-term debt$1.38B$2.17B$2.04B$1.95B$2.01B
Deferred revenue$1.49B$1.51B$1.4B$1.11B$0.00
Total current liabilities$20B$19.4B$19.6B$18.7B$15.5B
Long-term debt$31.9B$30.5B$24.6B$23.9B$22.9B
Deferred revenue, non-current$0.00$0.00$0.00$1.11B$1.15B
Total non-current liabilities$57.5B$56B$50B$47.8B$45.8B
Capital lease obligations$529M$658M$685M$751M$864M
Total liabilities$77.5B$75.5B$69.5B$66.4B$61.3B
Common stock$2M$2M$2M$2M$2M
Retained earnings$35.4B$33.5B$31.7B$29.6B$27.1B
Accumulated other comprehensive income (loss)-$-451M-$-1.15B-$-1.31B-$-2.49B-$-178M
Total equity$44B$41.4B$39.4B$36.3B$36.1B
Total investments$38.6B$37.2B$36.8B$33.3B$34B
Total debt$33.2B$32.7B$26.7B$25.8B$24.9B
Net debt$23.7B$24.4B$20.1B$18.4B$20B
Cash flow statement
20252024202320222021
Net income$5.66B$5.97B$5.99B$6.02B$6.1B
Depreciation and amortization$1.55B$1.39B$1.75B$1.68B$1.3B
Stock-based compensation$276M$191M$289M$264M$255M
Change in working capital-$-3.28B-$-1.72B-$-535M$253M$784M
Accounts receivable-$-2.53B-$-683M-$-1.76B-$-2.51B-$-2.14B
Inventory$0.00$0.00$0.00$2.51B$2.14B
Accounts payable-$-720M-$-272M$1.64B$252M$719M
Net cash provided by operating activities$4.29B$5.81B$8.06B$8.4B$8.36B
Investments in property, plant and equipment-$-1.12B-$-1.26B-$-1.3B-$-1.15B-$-1.09B
Acquisitions, net$88M-$-4.45B-$-1.55B-$-649M-$-3.48B
Net cash used for investing activities-$-1.34B-$-5.17B-$-5.57B-$-4.56B-$-9.64B
Common stock issued$0.00$0.00$0.00$0.00$0.00
Common stock repurchased-$-2.61B-$-2.9B-$-2.68B-$-2.32B-$-1.9B
Dividends paid-$-1.53B-$-1.51B-$-1.4B-$-1.23B-$-1.1B
Net cash used for financing activities-$-1.74B$1.19B-$-3.35B-$-1.32B$423M
Net change in cash$1.2B$1.76B-$-861M$2.51B-$-861M
Cash at end of period$9.49B$8.29B$6.53B$7.39B$4.88B
Operating cash flow$4.29B$5.81B$8.06B$8.4B$8.36B
Capital expenditure-$-1.12B-$-1.26B-$-1.3B-$-1.15B-$-1.09B
Free cash flow$3.17B$4.55B$6.77B$7.25B$7.28B
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Elevance Health Inc.

        Operating as a major health benefits organization, Elevance Health Inc. commits to guiding consumers, families, and communities across their entire health and wellness path. It facilitates access to vital care, assistance, and tools designed to enable healthier living for approximately 118 million individuals. The company's comprehensive offerings span medical, digital, pharmaceutical, behavioral health, clinical, and other care solutions. Founded in 1944 and based in Indianapolis, Indiana, this entity adopted its current name, Elevance Health Inc., in June 2022, having previously operated as Anthem, Inc.

        CEO
        Gail Koziara Boudreaux
        Employees
        97.1K
        Beta
        0.68

        Explore

        Frequently asked questions

        What is the intrinsic value of Elevance Health Inc. (ELV)?

        Elevance Health Inc. (ELV) is currently overvalued based on the InvestorsCraft IC model — IC value is 20–50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is ELV undervalued?

        ELV trades at a price of $394.48 (Nov 21, 2026): overvalued — IC value is 20–50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.